{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:53:30Z","timestamp":1793566410763,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04504-6","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:38:15Z","timestamp":1762342695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between serum uric acid levels and primary aldosteronism"],"prefix":"10.1186","volume":"26","author":[{"given":"Xuying","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongzheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuqi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"5","key":"4504_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case Detection, Diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26934393.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"4504_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens. 2020;38(10):1919\u201328. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32890264.","journal-title":"J Hypertens"},{"issue":"14","key":"4504_CR3","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811\u201320. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28385310.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"4504_CR4","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.eprac.2020.10.007","volume":"27","author":"F Xu","year":"2021","unstructured":"Xu F, Gao Z, Wang G, et al. Prevalence, subtype Classification, and outcomes of treatment of primary aldosteronism: A prospective study in China. Endocr Pract. 2021;27(5):478\u201383. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33853742.","journal-title":"Endocr Pract"},{"issue":"4","key":"4504_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ecl.2019.08.002","volume":"48","author":"GL Hundemer","year":"2019","unstructured":"Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management: A clinical approach. Endocrinol Metab Clin North Am. 2019;48(4):681\u2013700. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31655770.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"4504_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41\u201350. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29129575.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"4504_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29129576.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"839","key":"4504_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/pgmj.71.839.561","volume":"71","author":"UM Kabadi","year":"1995","unstructured":"Kabadi UM. Renal calculi in primary hyperaldosteronism. Postgrad Med J. 1995;71(839):561\u20132. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7479473.","journal-title":"Postgrad Med J"},{"key":"4504_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-physiol-021113-170343","volume":"77","author":"AK Mandal","year":"2015","unstructured":"Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323\u201345. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25422986.","journal-title":"Annu Rev Physiol"},{"key":"4504_CR10","doi-asserted-by":"crossref","unstructured":"Enomoto A, Kimura H, Chairoungdua A et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447\u2009\u2013\u200952. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12024214.","DOI":"10.1038\/nature742"},{"issue":"12","key":"4504_CR11","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1097\/HJH.0000000000002948","volume":"39","author":"KM Chen","year":"2021","unstructured":"Chen KM, Chang YL, Wu TH, et al. Aldosterone-producing adenoma-harbouring KCNJ5 mutations is associated with lower prevalence of metabolic disorders and abdominal obesity[J]. J Hypertens. 2021;39(12):2353\u201360. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34313632.","journal-title":"J Hypertens"},{"issue":"12","key":"4504_CR12","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1210\/jc.2018-00866","volume":"103","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Sone M, Inagaki N, et al. Obesity as a key factor underlying idiopathic hyperaldosteronism[J]. J Clin Endocrinol Metabolism. 2018;103(12):4456\u201364. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30165444.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"2","key":"4504_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454\u20139. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16291704.","journal-title":"J Clin Endocrinol Metab"},{"key":"4504_CR14","doi-asserted-by":"publisher","first-page":"565714","DOI":"10.3389\/fendo.2021.565714","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Chen X, Chen Q, et al. Non-Alcoholic fatty liver disease and hypokalemia in primary aldosteronism among Chinese population. Front Endocrinol (Lausanne). 2021;12:565714. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33967948.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"4504_CR15","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1210\/jc.2012-3934","volume":"98","author":"E Fischer","year":"2013","unstructured":"Fischer E, Adolf C, Pallauf A, et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab. 2013;98(6):2513\u201320. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23539730.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"4504_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1161\/HYPERTENSIONAHA.108.122002","volume":"53","author":"J Matrozova","year":"2009","unstructured":"Matrozova J, Steichen O, Amar L, et al. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2009;53(4):605\u201310. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19221213.","journal-title":"Hypertension"},{"issue":"3","key":"4504_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cen.13370","volume":"87","author":"M Tancredi","year":"2017","unstructured":"Tancredi M, Johannsson G, Eliasson B, et al. Prevalence of primary aldosteronism among patients with type 2 diabetes. Clin Endocrinol (Oxf). 2017;87(3):233\u201341. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28493291.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4504_CR18","doi-asserted-by":"publisher","first-page":"547356","DOI":"10.3389\/fendo.2020.547356","volume":"11","author":"SL Zhang","year":"2020","unstructured":"Zhang SL, Gao JW, Guo Y, et al. Associations between metabolic profiles and Target-Organ damage in Chinese individuals with primary aldosteronism. Front Endocrinol (Lausanne). 2020;11:547356. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33101195.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4504_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000484283","volume":"192","author":"C King","year":"2018","unstructured":"King C, Lanaspa MA, Jensen T, et al. Uric acid as a cause of the metabolic syndrome. Contrib Nephrol. 2018;192:88\u2013102. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29393133.","journal-title":"Contrib Nephrol"},{"issue":"9","key":"4504_CR20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s42255-021-00454-z","volume":"3","author":"A Andres-Hernando","year":"2021","unstructured":"Andres-Hernando A, Cicerchi C, Kuwabara M, et al. Umami-induced obesity and metabolic syndrome is mediated by nucleotide degradation and uric acid generation. Nat Metab. 2021;3(9):1189\u2013201. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34552272.","journal-title":"Nat Metab"},{"issue":"6","key":"4504_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2174\/1570161118666191217123930","volume":"18","author":"F Cortese","year":"2020","unstructured":"Cortese F, Scicchitano P, Cortese AM, et al. Uric acid in metabolic and cerebrovascular disorders: A review. Curr Vasc Pharmacol. 2020;18(6):610\u20138. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31845632.","journal-title":"Curr Vasc Pharmacol"},{"issue":"5","key":"4504_CR22","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case Detection, Diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"4504_CR23","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens. 2020;38(10):1919\u201328.","journal-title":"J Hypertens"},{"issue":"1","key":"4504_CR24","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/EJE-17-0990","volume":"179","author":"TA Williams","year":"2018","unstructured":"Williams TA, Reincke M, MANAGEMENT OF ENDOCRINE DISEASE. Diagnosis and management of primary aldosteronism: the endocrine society guideline 2016 revisited. Eur J Endocrinol. 2018;179(1):R19\u201329. https:\/\/doi.org\/10.1530\/EJE-17-0990.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"4504_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1210\/jc.2011-2830","volume":"97","author":"GP Rossi","year":"2012","unstructured":"Rossi GP, Barisa M, Allolio B, et al. The adrenal vein sampling international study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012;97(5):1606\u201314.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4504_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ejendo\/lvaf117","volume":"193","author":"M Murakami","year":"2025","unstructured":"Murakami M, Naruse M, Kobayashi H, et al. Expert consensus on the primary aldosteronism severity classification and its strategic application in indicating adrenal venous sampling. Eur J Endocrinol. 2025;193(1):85\u201396. https:\/\/doi.org\/10.1093\/ejendo\/lvaf117.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"4504_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2143\/AC.61.4.2017299","volume":"61","author":"H Ebinc","year":"2006","unstructured":"Ebinc H, Ebinc FA, Ozkurt ZN, et al. Relationship of left ventricular mass to insulin sensitivity and body mass index in healthy individuals. Acta Cardiol. 2006;61(4):398\u2013405. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16970048.","journal-title":"Acta Cardiol"},{"issue":"28","key":"4504_CR28","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34(28):2159\u2013219. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23771844.","journal-title":"Eur Heart J"},{"issue":"2","key":"4504_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/HJH.0000000000001511","volume":"36","author":"T Yamashita","year":"2018","unstructured":"Yamashita T, Shimizu S, Koyama M, et al. Screening of primary aldosteronism by clinical features and daily laboratory tests: combination of urine pH, sex, and serum K. J Hypertens. 2018;36(2):326\u201334. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28832364.","journal-title":"J Hypertens"},{"issue":"3","key":"4504_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/cen.14142","volume":"92","author":"N Kietsiriroje","year":"2020","unstructured":"Kietsiriroje N, Wonghirundecha R, Suntornlohanakul O, et al. Construction of a predictive scoring system as a guide to screening and confirmation of the diagnosis of primary aldosteronism. Clin Endocrinol (Oxf). 2020;92(3):196\u2013205. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31840266.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"4504_CR31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12020-021-02745-7","volume":"73","author":"MH Wang","year":"2021","unstructured":"Wang MH, Li NF, Luo Q, et al. Development and validation of a novel diagnostic nomogram model to predict primary aldosteronism in patients with hypertension. Endocrine. 2021;73(3):682\u201392. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34028647.","journal-title":"Endocrine"},{"issue":"8","key":"4504_CR32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/jch.13041","volume":"19","author":"A Tirosh","year":"2017","unstructured":"Tirosh A, Hannah-Shmouni F, Lyssikatos C, et al. Obesity and the diagnostic accuracy for primary aldosteronism. J Clin Hypertens (Greenwich). 2017;19(8):790\u20137. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28612447.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"7","key":"4504_CR33","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1210\/jc.2008-0251","volume":"93","author":"GP Rossi","year":"2008","unstructured":"Rossi GP, Belfiore A, Bernini G, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008;93(7):2566\u201371. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18445663.","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"4504_CR34","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.jacc.2020.02.052","volume":"75","author":"Z Xu","year":"2020","unstructured":"Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension. J Am Coll Cardiol. 2020;75(16):1913\u201322. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32327102.","journal-title":"J Am Coll Cardiol"},{"key":"4504_CR35","doi-asserted-by":"crossref","unstructured":"Namba M, Kikuchi K, Komura H et al. Study on uric acid metabolism in patients with primary aldosteronism. Nihon Naibunpi Gakkai Zasshi. 1992;68(1):51\u201361. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1541367.","DOI":"10.1507\/endocrine1927.68.1_51"},{"key":"4504_CR36","unstructured":"Deng YJ, Zhang SL, Liu PM et al. Comparison on metabolic disorders and uric acid levels between patients with primary aldosteronism and essential hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(9):743\u2013749. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27667270."},{"issue":"2","key":"4504_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/13697130802607719","volume":"12","author":"M Koga","year":"2009","unstructured":"Koga M, Saito H, Mukai M, et al. Factors contributing to increased serum urate in postmenopausal Japanese females. Climacteric. 2009;12(2):146\u201352. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19105055.","journal-title":"Climacteric"},{"issue":"1","key":"4504_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.atherosclerosis.2015.03.030","volume":"241","author":"L Barbieri","year":"2015","unstructured":"Barbieri L, Verdoia M, Schaffer A, et al. Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study. Atherosclerosis. 2015;241(1):241\u20138. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25818387.","journal-title":"Atherosclerosis"},{"issue":"1","key":"4504_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/03630242.2021.2019170","volume":"62","author":"RS Feitosa","year":"2022","unstructured":"Feitosa RS, Martins BP, Almeida LM, et al. Serum uric acid is independently associated with metabolic syndrome and systemic hypertension in women from Northeast Brazil. Women Health. 2022;62(1):68\u201374. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34965850.","journal-title":"Women Health"},{"key":"4504_CR40","doi-asserted-by":"crossref","unstructured":"Yanai H, Adachi H, Hakoshima M et al. Molecular biological and clinical Understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic Syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021;22(17). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34502127.","DOI":"10.3390\/ijms22179221"},{"key":"4504_CR41","doi-asserted-by":"crossref","unstructured":"Iimura O, Shimamoto K. Salt and hypertension: water-sodium handling in essential hypertension. Ann N Y Acad Sci, 1993;676:105\u2009\u2013\u200921. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8489125.","DOI":"10.1111\/j.1749-6632.1993.tb38729.x"},{"key":"4504_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","volume":"94","author":"S Patel","year":"2017","unstructured":"Patel S, Rauf A, Khan H, et al. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017;94:317\u201325. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28772209.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4504_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/ajh.2011.216","volume":"25","author":"JJ Sim","year":"2012","unstructured":"Sim JJ, Bhandari SK, Shi J, et al. Plasma Renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. Am J Hypertens. 2012;25(3):379\u201388. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22158065.","journal-title":"Am J Hypertens"},{"issue":"1","key":"4504_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1507\/endocrine1927.68.1_51","volume":"68","author":"M Namba","year":"1992","unstructured":"Namba M, Kikuchi K, Komura H, et al. Nihon Naibunpi Gakkai Zasshi. 1992;68(1):51\u201361. https:\/\/doi.org\/10.1507\/endocrine1927.68.1_51.","journal-title":"Nihon Naibunpi Gakkai Zasshi"},{"issue":"7","key":"4504_CR45","doi-asserted-by":"publisher","first-page":"bvae109","DOI":"10.1210\/jendso\/bvae109","volume":"8","author":"J Yang","year":"2024","unstructured":"Yang J, McCarthy J, Shah SS, et al. Challenges in diagnosing and managing the spectrum of primary aldosteronism. J Endocr Soc. 2024;8(7):bvae109. https:\/\/doi.org\/10.1210\/jendso\/bvae109. Published 2024 Jun 4.","journal-title":"J Endocr Soc"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04504-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:38:16Z","timestamp":1762342696000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04504-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4504"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04504-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Review Board of the Affiliated Hospital of Nantong University (No.: 2021-K099-02). All participating patients provided written informed consent for the utilization of their clinical data in scientific research. All methods were carried out in accordance with Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"618"}}